Requirements for the clinical evaluation of new anti-tuberculosis agents in children

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 6, 2013, Pages 794-799

  Donald, Peter Roderick ^a   Ahmed, A ^b,c   Burman, W J ^d   Cotton, M F ^a   Graham, S M ^e   Mendel, C ^f   McIlleron, H ^g   Mac Kenzie, W R ^h   Nachman, S ⁱ   Schaaf, H S ^a   Starke, J R ^j   Wingfield, C ^k   Hesseling, Anneke C ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b CAROLINAS MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d DENVER PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f Global Alliance for TB Drug Development   (United States)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

ⁱ STONY BROOK UNIVERSITY   (United States)

^j BAYLOR COLLEGE OF MEDICINE   (United States)

^k TB HIV Project Treatment Action Group   (United States)

more..

Author keywords

Children; Drugs; Evaluation; Framework; Requirements; Tuberculosis

Indexed keywords

TUBERCULOSTATIC AGENT;

ARTICLE; AWARENESS; CHEMOPROPHYLAXIS; CLINICAL EVALUATION; DRUG DISPOSITION; DRUG FORMULATION; DRUG RESPONSE; EVIDENCE BASED MEDICINE; HEALTH PROGRAM; HUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ADULT; AGE FACTORS; ANTITUBERCULAR AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; EVIDENCE-BASED MEDICINE; HUMANS; RESEARCH DESIGN; TUBERCULOSIS;

EID: 84878282341     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0567     Document Type: Article

References (33)

1. Krekels E H, van den Anker J N, Baiardi P, et al. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 2007; 8: 1787-1799. (Pubitemid 47316143)
2. McNeeley D F, Raoof A, Lin J, Marais B J. Chapter 24: The evaluation of new anti-tuberculosis drugs in children. In: Donald P R, van Helden P D, eds. Anti-tuberculosis chemotherapy. Progress in respiratory research, Vol 40. Basel, Switzerland; Karger, 2011.
3. Shirkey H. Therapeutic orphans. J Pediatr 1968; 72: 119-120.
4. Nuermberger E L, Spigelman M K, Yew W W. Current development and future prospects in chemotherapy of tuberculosis. Respirology 2010; 15: 764-778.
5. Ernest T B, Elder D P, Martini L G, Roberts M, Ford J L. Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 2007; 59: 1043-1055. (Pubitemid 47265351)
6. Burman W J, Cotton M F, Gibb D M, Walker A S, Vernon A A, Donald P R. Ensuring the involvement of children in the evaluation of new tuberculosis treatment regimens. PLoS Med 2008; 5: e176.
7. Swedish National Association Against Tuberculosis, Therapeutic Trials Committee. Para-aminosalicylic acid treatment in pulmonary tuberculosis. Am Rev Tuberc 1950; 61: 597-612.
8. Medical Research Council. Isoniazid in combination with streptomycin or PAS in the treatment of pulmonary tuberculosis. Brit Med J 1953; 2: 1005-1014.
9. Nelson L J, Wells C D. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004; 8: 636-647. (Pubitemid 38625076)
10. Marais B J, Donald P R, Gie R P, Schaaf H S, Beyers N. Diversity of disease in childhood pulmonary tuberculosis. Ann Trop Paediatr 2005; 25: 79-86. (Pubitemid 41131125)
11. Lincoln E M, Harris L C, Bovronkitt S, Carretero R W. Endobronchial tuberculosis in children, a study of 156 patients. Am Rev Tuberc 1958; 77: 39-61.
12. Weber H C, Beyers N, Gie R P, Schaaf H S, Fish T, Donald P R. The clinical and radiological features of tuberculosis in adolescents. Ann Trop Paediatr 2000; 20: 5-10. (Pubitemid 30171221)
13. Zar H J, Hanslo D, Apolles P, Swingler G, Hussey G. Induced sputum versus gastric lavage for microbiological confirmation of pulmonary tuberculosis in infants and young children: a prospective study. Lancet 2005; 365: 130-134. (Pubitemid 40091802)
14. Fox T G. Occult tuberculous infection in children. Tubercle 1977; 58: 91-96. (Pubitemid 8103600)
15. Toppet M, Malfroot A, Hofman B, Casimir G, Cantraine F, Dab I. Tuberculosis in children: a 13-year follow up of 1714 patients in a Belgian home care centre. Eur J Pediatr 1991; 150: 331-335.
16. Schaaf H S, Beyers N, Gie R P, et al. Respiratory tuberculosis in childhood: the diagnostic value of clinical features and special investigations. Pediatr Infect Dis J 1995; 14: 189-194.
17. Wallgren A. Primary tuberculous infections in young adult life and in childhood with reference to their relative advantages and disadvantages. Am J Dis Child 1941; 61: 577-589.
18. Wiseman C A, Schaaf H S, Cotton M F, et al. Bacteriologically confirmed tuberculosis in HIV-infected infants: disease spectrum and survival. Int J Tuberc Lung Dis 2011; 15: 770-775.
19. Abernathy R S, Dutt A K, Stead W W, Moers D J. Short-course chemotherapy for tuberculosis in children. Pediatrics 1983; 72: 801-806. (Pubitemid 14206995)
20. Ramachandran P, Kripasankar A S, Duraipandian M. Short-course chemotherapy for pulmonary tuberculosis in children. Indian J Tuberc 1998; 45: 83-87.
21. Al-Dossary F S, Ong L T, Correa A G, Starke J R. Treatment of childhood tuberculosis with a six-month directly observed regimen of only two weeks of daily therapy. Pediatr Infect Dis J 2002; 21: 91-97. (Pubitemid 34150604)
22. Swaminathan S, Raghavan A, Duraipandian M, Kripasankar A S, Ramachandran P. Short-course chemotherapy for paediatric respiratory tuberculosis: 5-year report. Int J Tuberc Lung Dis 2005; 9: 693-696. (Pubitemid 40826165)
23. McCarver D. Applicability of the principles of developmental pharmacology to the study of environmental toxicants. Pediatrics 2004; 113: 969-972. (Pubitemid 38437349)
24. Kearns G L, Abdel-Rahman S M, Alander S W, Blowey D L, Leeder J S, Kauffman R E. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167. (Pubitemid 37122329)
25. Anderson B J. Problems and pitfalls performing pharmacokinetic studies in children. Paediatr Perinat Drug Ther 2007; 8: 4-17. (Pubitemid 47619345)
26. Hines R N, McCarver D G. The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-360. (Pubitemid 34106223)
27. McCarver D G, Hines R N. The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 2002; 300: 361-366. (Pubitemid 34106224)
28. Johnsrud E K, Koukouritaki S B, Divakaran K, Brunengraber L L, Hines R N, McCarver D G. Human hepatic CYP2E1 expression during development. J Pharmacol Exp Ther 2003; 307: 402-407. (Pubitemid 37151933)
29. Koukouritaki S B, Manro J R, Marsh S A, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308: 965-974. (Pubitemid 38263972)
30. McIlleron H, Ren Y, Nuttall J, Fairlie L, et al. Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011; 16: 417-421.
31. Oudijk J M, McIlleron H, Mulenga V, et al. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment. AIDS 2012; 26: 1523-1528.
32. Cuevas L E, Browning R, Bossuyt P, et al. Evaluation of tuberculosis diagnostics in children: 2. methodological issues for conducting and reporting research evaluations of tuberculosis diagnostics for intrathoracic tuberculosis in children. Consensus from an expert panel. J Infect Dis 2012; 205 (Suppl 2): S209-S215.
33. Graham S M, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205 (Suppl 2): S199-S208.